Song et al. [62] suggested along similar lines that a structural change in the BH3-binding groove is caused by phosphorylation of BCL-2, providing a basis to overcome this resistance of CLL cells by adding kinase inhibitors with venetoclax therapy. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.